Si-bone Stock Earnings Reports

SI-BONE reported solid Q1 2026 results with worldwide revenue of $52.6M, up 11.2% year-over-year (U.S. $49.3M, +10%; International $3.3M, +33.9%). The company highlighted strong physician engagement (record ~1,650 active physicians, +17% YoY), continued commercial productivity (89 quota-carrying territories, $2.2M annual revenue per territory, 14th consecutive quarter of double-digit territory productivity growth), and a hybrid sales model augmented by ~300 third-party agents. SI-BONE advanced multiple product initiatives: launched INTRA Ti and expanded TORQ/TNT internationally, completed initial Smith+Nephew trauma field rollout (training expected complete by end of Q2 with revenue contribution starting in H2), and reaffirmed a third breakthrough-designated device targeting a Q3 510(k) submission and a planned Q4 launch. Financially, gross margin remained strong at ~79.8% (guidance raised to ~79% for the year), operating expenses grew modestly (~4.1%), net loss narrowed to $4.3M, and adjusted EBITDA improved to $2.5M (over 440% YoY improvement). The company raised full-year 2026 revenue guidance to $230M–$233M (implying ~14%–16% growth) and emphasized free cash flow improvement and ample liquidity ($144.7M cash and marketable securities). A potentially material reimbursement development: CMS proposed new DRG families that could increase average hospital payment for procedures using Granite by up to ~$50,000 (if finalized, effective Oct 1), which management sees as a strong tailwind for Granite adoption and broader spinal pelvic opportunity. Management expects revenue acceleration through 2026 into 2027 driven by product launches, the Smith+Nephew partnership, international expansion, and favorable reimbursement dynamics.